Galena Biopharma Company Profile (NASDAQ:GALE)

Analyst Ratings

Consensus Ratings for Galena Biopharma (NASDAQ:GALE) (?)
Ratings Breakdown: 3 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $3.00 (538.30% upside)

Analysts' Ratings History for Galena Biopharma (NASDAQ:GALE)
Show:
DateFirmActionRatingPrice TargetActions
7/22/2016FBR & CoReiterated RatingOutperform$5.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016Maxim GroupReiterated RatingBuy$4.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2016S&P Equity ResearchLower Price Target$0.61 -> $0.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Noble FinancialDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Raymond James Financial Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015Cantor FitzgeraldUpgradeSell -> Hold$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015MLV & Co.Reiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2015Needham & Company LLCSet Price TargetBuy$7.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Galena Biopharma (NASDAQ:GALE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q1($0.06)($0.07)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4($0.05)($0.07)$2.61 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.07)($0.11)$4.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.09)($0.10)$3.54 million$3.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.09)($0.08)$3.47 million$2.75 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414($0.11)($0.06)$2.58 million$3.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.11)($0.05)$2.66 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.09)($0.17)$2.99 million$2.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.10)($0.02)$2.09 million$2.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.09)($0.46)$1.62 million$1.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q213($0.10)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2013Q4 2012($0.62)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.09)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galena Biopharma (NASDAQ:GALE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.05)($0.05)($0.05)
Q2 20161($0.08)($0.08)($0.08)
Q3 20161($0.08)($0.08)($0.08)
Q4 20162($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galena Biopharma (NASDAQ:GALE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galena Biopharma (NASDAQ:GALE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/12/2014Richard ChinDirectorSell187,500$4.33$811,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014Rudolph NisiDirectorBuy20,000$4.94$98,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Mark SchwartzCOOSell100,000$5.57$557,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Sanford HillsbergDirectorSell250,000$5.41$1,352,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2014Rudolph NisiDirectorSell250,000$5.28$1,320,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2014Steven KriegsmanDirectorSell450,000$6.52$2,934,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Rudolph NisiDirectorSell200,000$6.90$1,380,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Galena Biopharma (NASDAQ:GALE)
DateHeadline
07/28/16 02:55 PMStocks Worth Mentioning Ratings-Wise: Unisys Corporation (NYSE:UIS), Galena Biopharma Inc (NASDAQ:GALE) - Review Fortune
07/28/16 02:55 PMEarnings in Focus: Galena Biopharma, Inc. (NASDAQ:GALE), The ... - News Oracle
07/28/16 02:55 PMNew Broker Ratings For Galena Biopharma, Inc. (GALE) - FTSE ... - FTSE News
07/28/16 04:02 AMActive biotech company shares in the news: Galena Biopharma, Inc. (NASDAQ:GALE), Celgene Corporation (NASDAQ ... - The Voice Registrar
07/26/16 10:20 PMGalena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on
07/26/16 04:17 PMStock under Analyst' Radar: Galena Biopharma, Inc. (NASDAQ:GALE) - News Oracle
07/26/16 04:17 PMRecent Analysts Ratings Fluctuations: Galena Biopharma, Inc ... - Street Updates
07/26/16 04:17 PMNotable Brokerage Recommendations: Galena Biopharma Inc ... - Review Fortune
07/26/16 06:05 AMGalena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, August 9, 2016 - [GlobeNewswire] - SAN RAMON, Calif., July 26, 2016-- Galena Biopharma, a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, ...
07/26/16 04:19 AMHC Stocks Reports Analysis: Galena Biopharma Inc (NASDAQ ... - share market updates (press release)
07/25/16 09:41 PMBRIEF-Galena Biopharma files for secondary offering of upto 3.7 mln shares - SEC filing
07/25/16 08:48 AMEvolent Health, Inc. (NYSE:EVH) increased 4.30%: Galena Biopharma Inc (NASDAQ:GALE), Perrigo Company plc ... - KC Register
07/25/16 08:48 AMAnalysts: Galena Biopharma, Inc. (NASDAQ:GALE) stock is worth $1.47 - Review Fortune
07/23/16 08:13 AMFDA raises concerns over Valeant's eye drop
07/22/16 04:04 PMHC Stocks Reports: Galena Biopharma Inc (NASDAQ:GALE), Pfizer Inc. (NYSE:PFE) - share market updates (press release)
07/22/16 04:03 PMFBR Slashes Price Target For Galena Biopharma Inc (GALE); Reiterates Positive Stance - Smarter Analyst
07/22/16 07:02 AMForm 4 Galena Biopharma, Inc. For: Jul 14 Filed by: Nisi Rudolph - StreetInsider.com
07/22/16 07:02 AMEarnings Focus and Crowd Sourced Sentiment Review for Galena Biopharma, Inc. (NASDAQ:GALE) - TGP
07/20/16 05:32 PMGalena Biopharma, Inc. (GALE) Current Analyst Ratings - Fiscal Standard
07/20/16 05:32 PMGalena Biopharma Inc. (GALE) Jumps 27.39% on July 20 - Equities.com
07/20/16 07:55 AMGalena Biopharma (GALE) is Oversold: Can It Recover? -
07/20/16 07:00 AMAnalysts Watching Stocks Update: Galena Biopharma, Inc. (NASDAQ:GALE) , MannKind Corporation (NASDAQ:MNKD) - Street Updates
07/19/16 10:16 AMGalena Biopharma, Inc. (NASDAQ:GALE) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/19/16 10:16 AMEquity Roundup: Stock Performance Focus on Galena Biopharma, Inc. (NASDAQ:GALE) - Press Telegraph
07/19/16 10:16 AMHC Stocks News: Galena Biopharma Inc (NASDAQ:GALE), Gilead Sciences, Inc. (NASDAQ:GILD) - share market updates (press release)
07/19/16 10:16 AMTrading the Biotech News: Kura Oncology, Inc. (NASDAQ:KURA), Galena Biopharma, Inc. (NASDAQ:GALE) - The Voice Registrar
07/19/16 10:16 AMActive biotech company shares in the news: Galena Biopharma, Inc. (NASDAQ:GALE), Vertex Pharmaceuticals ... - The Voice Registrar
07/18/16 03:03 PMGALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib -
07/16/16 03:58 PMBRIEF-CVI Investments reports 6.7 pct passive stake in Galena Biopharma
07/16/16 07:33 AMHow Many Galena Biopharma Inc (NASDAQ:GALE)'s Analysts Are Bearish? - Press Telegraph
07/15/16 03:08 PMStocks Trend Analysis: Galena Biopharma, Inc. (GALE) QEP Resources, Inc. (QEP) Devon Energy Corporation (DVN) - iStreetWire
07/14/16 09:29 PMStocks Roundup: Galena Biopharma Inc (NASDAQ:GALE), Whiting Petroleum Corp (NYSE:WLL) - NYSE Journal (press release)
07/14/16 04:16 PMStock under Radar: Galena Biopharma, Inc. (NASDAQ:GALE) - News Oracle
07/14/16 07:30 AMGalena Biopharma, Inc. (NASDAQ:GALE) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/14/16 07:30 AMGalena Biopharma (NASDAQ:GALE) & Eli Lilly and Co (NYSE:LLY) Stocks are Roundup - Money News (press release)
07/14/16 07:30 AMStocks Movements Activity: Galena Biopharma, Inc. (NASDAQ:GALE) , Wright Medical Group N.V. (NASDAQ:WMGI) - Street Updates
07/13/16 03:35 PMGalena Biopharma Announces Closing of Registered Direct Offering - [GlobeNewswire] - SAN RAMON, Calif., July 13, 2016-- Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical ...
07/13/16 04:09 AMStock under Analysts' radar: Galena Biopharma, Inc. (NASDAQ:GALE) - News Oracle
07/12/16 09:29 PMHC Stocks Watchful: Galena Biopharma Inc (NASDAQ:GALE), Orexigen Therapeutics, Inc. (NASDAQ:OREX) - share market updates (press release)
07/12/16 04:22 PMBRIEF-Sabby Management LLC reports 6.67 pct passive stake in Galena Biopharma
07/12/16 05:08 AMGALENA BIOPHARMA, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities -
07/11/16 04:11 PMAnalysts: Galena Biopharma, Inc. (NASDAQ:GALE) stock is worth $3.13 - Review Fortune
07/11/16 04:11 PMIs Galena Biopharma Inc (NASDAQ:GALE) Just Down, Or Is It Out? - Insider Financial
07/09/16 03:50 PMBRIEF-Galena Biopharma says pricing of registered direct offering - Reuters
07/08/16 04:06 PMBRIEF-Galena Biopharma says pricing of registered direct offering
07/08/16 04:06 PMForm 4 Galena Biopharma, Inc. For: Jul 01 Filed by: Nejadnik Bijan
07/08/16 06:36 AMGALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Fina -
07/08/16 06:35 AMGalena Biopharma to Host Webcast and Conference Call Today - [GlobeNewswire] - SAN RAMON, Calif., July 08, 2016-- Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical ...
07/08/16 06:07 AM7:07 am Galena Biopharma prices a 28 mln share registered direct offering at $0.45/share with warrants to purchase up to 14 mln shares at $0.65/share in a concurrent private placement for gross proceeds of $12.6 mln -
07/08/16 06:05 AMGalena Biopharma Announces Pricing of Registered Direct Offering - [GlobeNewswire] - SAN RAMON, Calif., July 08, 2016-- Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major medical needs, ...

Social

About Galena Biopharma

Galena Biopharma logoGalena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GALE
  • CUSIP:
Key Metrics:
  • Previous Close: $0.47
  • 50 Day Moving Average: $1.13
  • 200 Day Moving Average: $1.16
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $85.46M
  • Beta: 1.88
  • Current Year EPS Consensus Estimate: $-0.24 EPS
  • Next Year EPS Consensus Estimate: $-0.12 EPS
Additional Links:
Galena Biopharma (NASDAQ:GALE) Chart for Friday, July, 29, 2016